Johnson & Johnson is enhancing its biotech portfolio with a $1 billion cash acquisition of Firefly Bio Inc. and a deal with Sail Biomedicines potentially worth $2.58 billion. This includes an upfront payment of $785 million and focuses on developing treatments for difficult solid tumors, with an anticipated R&D charge impacting earnings in 2026. The company’s stock remains above key moving averages, indicating a bullish long-term trend despite recent fluctuations. Currently trading at $258.03, JNJ shares are rated favorably on momentum and quality but show weaker value and growth scores.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.benzinga.com/trading-ideas/movers/26/07/60852016/johnson-johnson-shares-edge-higher-as-3-5b-biotech-moves-expand-oncology-pipeline
